🎯 Drug Targets

Browse 7 drug targets with druggability analysis, composite scores, and clinical context

7

Targets

0

High Druggability

0.55

Avg Score

15

Target Classes

Druggability Distribution

High: 0Medium: 0Low: 7Unknown: 0

Avg druggability score: 0.386

Clinical Pipeline

Approved: 2Phase III: 2Phase II: 2Phase I: 0Preclinical: 1

Total compounds: 24 · Approved: 0

Filtered by: class=receptor, druggability=Low — 7 results

TREM2 Triggering receptor expressed on myeloid cells 2 Phase II

Receptor Low Druggability

Agonist antibodies that enhance TREM2 signaling to promote microglial function

TFR1 Transferrin receptor protein 1 Approved

Receptor Low Druggability

Monoclonal antibodies targeting receptor or iron chelation affecting iron uptake

TLR4 Toll-like receptor 4 Phase III

Receptor Low Druggability

Small molecule antagonist or antibody blocking TLR4-mediated neuroinflammatory signaling

LRP1 LDL receptor related protein 1 Phase III

Receptor Low Druggability

Modulation of receptor-mediated endocytosis and clearance pathways

SDC1 Syndecan-1 Phase II

Receptor Low Druggability

Small molecule modulation of heparan sulfate interactions or shedding

IGF2R Insulin-like growth factor 2 receptor Approved

Receptor Low Druggability

Drugs targeting IGF2R typically work by blocking IGF2 binding and signaling through the IGF1R/IGF2R axis, thereby inhibiting mitogenic and anti-apoptotic effects in cancer cells. Alternatively, agents may enhance IGF2 clearance through IGF2R-mediated endocytosis to reduce circulating IGF2 levels and downstream signaling.

GPR109A Hydroxycarboxylic Acid Receptor 2 (HCAR2)

Receptor Low Druggability

Prioritized from 1 SciDEX hypotheses, including: Targeted Butyrate Supplementation for Microglial Phenotype Modulation